Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Lymphoid 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 3Wilms Tumor 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma 1Histiocytic Sarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

enzalutamide 1entinostat 1abemaciclib 1Polymerase Chain Reaction 1Pemetrexed 1Paclitaxel 1Midazolam 1Microarray Analysis 1Letrozole 1LY3023414 1In Situ Hybridization, Fluorescence 1Immunoenzyme Techniques 1Gene Expression Profiling 1Fulvestrant 1Flow Cytometry 1Fentanyl 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × LY3023414 × Lymphoid × Clear all
NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
156 enrolled
BreastLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡